Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1126 to 1140 of 1251 results for public health guidance

  1. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    Discontinued Reference number: GID-TA11128

    Technology appraisal guidance
    Discontinued

  2. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued Reference number: GID-TA11421

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued Reference number: GID-TA11020

    Technology appraisal guidance
    Discontinued

  4. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    In development Reference number: GID-TA11606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]

    In development Reference number: GID-TA11670 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    Discontinued Reference number: GID-TA11647

    Technology appraisal guidance
    Discontinued

  8. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    Discontinued Reference number: GID-TA11033

    Technology appraisal guidance
    Discontinued

  9. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    Discontinued Reference number: GID-TA11034

    Technology appraisal guidance
    Discontinued

  10. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    Discontinued Reference number: GID-TA11093

    Technology appraisal guidance
    Discontinued

  11. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    In development Reference number: GID-TA11299 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    Discontinued Reference number: GID-TA11252

    Technology appraisal guidance
    Discontinued

  13. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    Discontinued Reference number: GID-TA11344

    Technology appraisal guidance
    Discontinued

  14. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]

    In development Reference number: GID-TA11586 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development Reference number: GID-TA11500 Expected publication date: TBC

    Technology appraisal guidance
    In development